24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2020-02-26T10:44:55+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|0 Comments

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

30 04, 2019

TAmiRNA is part of the international IMI2 project “Translational Safety Biomarker Pipeline”

2019-12-09T09:20:21+01:00April 30th, 2019|biomarkers, drug development, drug discovery, exosomes, liquid biopsies, microRNAs, Personalized medicine, safety|0 Comments

Early and reliable detection and monitoring of adverse events is essential for improving of patient safety, reducing late attrition of drug candidates, and enhancing understanding of toxic mechanisms. The Translational Safety Biomarker Pipeline (TransBioLine) project will focus on development of biomarkers of injury for liver, kidney, pancreas, vasculature, central nervous system (CNS) and the development of non-invasive microRNA biomarkers using liquid biopsies. The project is coordinated by the University of Zurich with Pfizer as industry lead, and involves 27 partners (pharmaceutical companies, small and medium-sized enterprises, and academic institutions) from ten European countries and the United States of America. With a total budget of € 28 million, the EU and the pharmaceutical companies involved are financing the [...]

30 01, 2019

Ask the Expert: kit or service, NGS or qPCR – what is the best choice for my microRNA biomarker project?

2019-12-09T09:19:33+01:00January 30th, 2019|biomarkers, exosomes, liquid biopsies, LMD, microRNA services, microRNAs, osteomiR, thrombomiR|0 Comments

Can't find the answer to your question on our site? Not sure which method is right for your research? Get in touch with our experts at TAmiRNA - they will answer your questions and help to move from your ideas to results. Get in touch

8 08, 2018

Eager to learn more about TAmiRNA qPCR kits and the exciting field of microRNAs?

2019-12-09T09:18:58+01:00August 8th, 2018|biomarker, liquid biopsies, microRNAs, osteomiR, thrombomiR|0 Comments

Click here to read our Technotes

16 07, 2018

TAmiRNA receives FFG EARLY STAGE for the development of novel theranostic solutions based on microRNA biomarkers – the PATH project.

2019-12-09T09:18:35+01:00July 16th, 2018|biomarkers, exosomes, liquid biopsies, microRNAs|0 Comments

PATH stands for "Project for Advancing the Application of MicroRNAs as THeranostic Biomarkers". The aim of this project is to create optimal framework conditions for successful research and development of the application of microRNAs as theranostic biomarkers. “Theranostics” means the increasingly close integration of diagnostics and therapy. The aim of theranostics is to enable the right therapy for the right patient at the right time. A biomarker generally refers to a measurable indicator of a biological state or condition. MicroRNAs are a new class of biomarkers with enormous potential for applications in theranostics. They are short regulatory RNA molecules that are essential for the proper function of cells and tissues. The development of diseases is mostly due [...]